Item 2.02 Results of Operations and Financial Condition.
On July, 30, 2020, Alexion Pharmaceuticals, Inc. issued a press release relating
to its results of operations and financial condition for the quarter ended June
30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Form
8-K.
The attached press release contains both U.S. Generally Accepted Accounting
Principles, or GAAP, and non-GAAP financial measures. The non-GAAP results
exclude the impact of the following GAAP items: share-based compensation
expense, fair value adjustment of inventory acquired, amortization of purchased
intangible assets, changes in fair value of contingent consideration,
restructuring and related expenses, upfront payments related to licenses and
other strategic agreements, acquired in-process research and development,
impairment of purchased intangible assets, gains and losses related to strategic
equity investments, litigation charges, gain or loss on sale of a business or
asset, gain or loss related to purchase options, contingent milestone payments
associated with acquisitions of legal entities accounted for as asset
acquisitions, acquisition-related costs and certain adjustments to income tax
expense. Reconciliations between non-GAAP and GAAP financial measures are
included in the press release set forth as Exhibit 99.1 furnished in this Form
8-K. Alexion's management utilizes non-GAAP financial information to provide a
useful measure of comparative operating performance of Alexion. The non-GAAP
financial measures are supplemental to and not a substitute for, measures of
financial performance prepared in accordance with GAAP.
The press release, and the information set forth therein, is being furnished
pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the
"Exchange Act") or otherwise subject to the liabilities of that Section. Nor
shall such document be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, regardless of any general
incorporation language in the filing unless specifically stated so therein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release issued by Alexion Pharmaceuticals, Inc. on July 30, 2020
relating to its results of operations and financial condition for the quarter
ended June 30, 2020.
--------------------------------------------------------------------------------
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: July 30, 2020 ALEXION PHARMACEUTICALS, INC.
By: /s/ Doug Barry
Name: Doug Barry
Title: Vice President, Corporate Law
© Edgar Online, source Glimpses